Meta-Analysis of the Relationship between NM23 Expression to Gastric Cancer Risk and Clinical Features

Table 2

Overall analysis of CD133 expression association with clinical features.

	OR	95% CI
Gastric cancer risk	0.168	0.063–0.443	<0.001	50.20%	0.134
N stage	0.493	0.269–0.904	0.022	86.10%	0.052
TNM stage	0.47	0.32–0.70	<0.001	82.20%	0.401
Histological grade	0.476	0.319–0.711	0.001	60.30%	0.294
T stage	0.889	0.500–1.583	0.690	69.10%	0.606
Lymphatic invasion	0.801	0.343–1.874	0.609	73.00%	0.437
Vascular invasion	0.902	0.429–1.899	0.787	58.80%	0.835
5-Year OS rate	0.478	0.194–1.181	0.110	89.60%	0.074

, the value of Egger linear regression test for evaluating publication bias.